University of Chicago Medicine Comprehensive Cancer Center | Strategic Alliance Partners

May 02, 2024

Drs Merkow and Connell discuss the use of HAI therapy for patients with colorectal cancer.

April 30, 2024

Akriti Jain, MD, discusses the phase 1b VERONA study of venetoclax plus azacitidine in higher-risk myelodysplastic syndromes.

April 29, 2024

Rita Nanda, MD, discusses the importance of testing for HER2-low status in patients with early-stage breast cancer.

April 26, 2024

Rita Nanda, MD, discusses the evolution of treatment with CDK4/6 inhibitors in patients with hormone receptor-positive/HER2-negative breast cancer.

April 23, 2024

Rita Nanda, MD, discusses the evolution of treatment options for patients with HER2-low breast cancer.

April 18, 2024

Daniel Olson, MD, discusses toxicities associated with lifileucel and IL-2 in patients with unresectable or metastatic melanoma.

April 18, 2024

Nan Chen, MD, discusses the investigation of CDK4/6 inhibitors in early-stage breast cancer.

April 04, 2024

Rita Nanda, MD, discusses the future of neoadjuvant treatment for patients with HER2-positive breast cancer.

March 12, 2024

The University of Chicago Medicine treats patients with histotripsy, a technology that uses ultrasound energy to destroy liver tumors.

March 08, 2024

Sonali M. Smith, MD, discusses the value of mentorship in oncology practice on International Women’s Day.

March 08, 2024

Mecker G. Möller, MD, discusses the importance of addressing gender biases in oncology.

March 06, 2024

A new center at the University of Chicago Medicine will tackle health inequities in cancer.

March 05, 2024

Daniel Olson, MD, discusses the FDA approval of lifileucel for patients with advanced melanoma whose disease has been previously treated.

February 27, 2024

Daniel Olson, MD, discusses the significance of the FDA approval of lifileucel for patients with advanced melanoma.

January 08, 2024

Drs Donington and Stiles discuss the implications of perioperative immunotherapy trials on early-stage lung cancer management, definitions of resectability, and the incorporation of new multidisciplinary management guidance.

January 03, 2024

The expert panel closes its discussion with advice for community physicians and discusses the future treatment landscape for advanced non–small cell lung cancer.

December 27, 2023

The panel discusses the use of antibody-drug conjugates for patients with EGFR-mutant non–small cell lung cancer, with a focus on the HERTHENA-Lung01 and TROPION-Lung05 studies.

December 27, 2023

A panel of experts on non–small cell lung cancer provide their thoughts MARIPOSA-2, which studied amivantamab and chemotherapy in EGFR-mutant NSCLC in the second line and beyond.

December 20, 2023

Joshua K. Sabari, MD, reviews data from the MARIPOSA-2 trial and discusses treatment options in the second line and beyond for patients with EGFR-mutant non–small cell lung cancer.

December 20, 2023

The panel reacts to the MARIPOSA trial, which looked at amivantamab and lazertinib in the front line in patients with EGFR-mutant non–small cell lung cancer.